Zacks Investment Research upgraded shares of MEDNAX (NYSE:MD) from a sell rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. “

A number of other research analysts have also weighed in on the company. ValuEngine upgraded MEDNAX from a strong sell rating to a sell rating in a research report on Friday, August 3rd. Credit Suisse Group upgraded MEDNAX from a neutral rating to an outperform rating and raised their price objective for the company from $47.00 to $55.00 in a research report on Friday, August 3rd. Stifel Nicolaus set a $47.00 price objective on MEDNAX and gave the company a hold rating in a research report on Thursday, August 2nd. Leerink Swann began coverage on MEDNAX in a research report on Thursday, July 12th. They set a market perform rating and a $50.00 price objective for the company. Finally, Citigroup cut their price objective on MEDNAX from $57.00 to $50.00 and set a neutral rating for the company in a research report on Friday, May 4th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. MEDNAX presently has an average rating of Hold and an average price target of $54.71.

Shares of MEDNAX stock opened at $47.74 on Tuesday. The stock has a market cap of $4.43 billion, a PE ratio of 15.16, a PEG ratio of 1.26 and a beta of 0.19. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.59. MEDNAX has a twelve month low of $40.56 and a twelve month high of $63.04.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $1.07 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $1.07. The firm had revenue of $915.90 million during the quarter, compared to analyst estimates of $911.77 million. MEDNAX had a return on equity of 10.42% and a net margin of 9.59%. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.85 earnings per share. analysts anticipate that MEDNAX will post 3.76 earnings per share for the current fiscal year.

In related news, insider John C. Pepia sold 3,000 shares of the stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $46.43, for a total value of $139,290.00. Following the completion of the transaction, the insider now owns 39,716 shares of the company’s stock, valued at approximately $1,844,013.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Dominic J. Andreano sold 18,000 shares of the stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $46.95, for a total transaction of $845,100.00. Following the completion of the transaction, the senior vice president now directly owns 24,896 shares of the company’s stock, valued at approximately $1,168,867.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,251 shares of company stock valued at $3,462,384. 2.40% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. Raymond James & Associates increased its stake in shares of MEDNAX by 156.5% in the fourth quarter. Raymond James & Associates now owns 12,554 shares of the company’s stock valued at $671,000 after buying an additional 7,660 shares in the last quarter. Macquarie Group Ltd. increased its stake in shares of MEDNAX by 36.1% in the fourth quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after buying an additional 1,300 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of MEDNAX by 0.6% in the first quarter. Wells Fargo & Company MN now owns 843,529 shares of the company’s stock valued at $46,926,000 after buying an additional 4,647 shares in the last quarter. Dupont Capital Management Corp increased its stake in shares of MEDNAX by 874.8% in the first quarter. Dupont Capital Management Corp now owns 71,092 shares of the company’s stock valued at $3,955,000 after buying an additional 63,799 shares in the last quarter. Finally, MUFG Securities EMEA plc increased its stake in shares of MEDNAX by 217.5% in the first quarter. MUFG Securities EMEA plc now owns 667,600 shares of the company’s stock valued at $37,139,000 after buying an additional 457,300 shares in the last quarter. 95.63% of the stock is owned by hedge funds and other institutional investors.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Featured Story: Trading Strategy Methods for Individual Investors

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.